FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945852816> ?p ?o ?g. }

• W2945852816 endingPage "794" @default.
• W2945852816 startingPage "781" @default.
• W2945852816 abstract "As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide.We did a randomised, open-label, phase 3 trial at 133 hospitals and research centres in 21 countries. We enrolled patients (aged ≥18 years) with a diagnosis of multiple myeloma and measurable disease, an Eastern Cooperative Oncology Group performance status of 0-2, who received one to three previous regimens, including a lenalidomide-containing regimen for at least two consecutive cycles. We randomly assigned patients (1:1) to bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks of four, stratified according to age, number of previous regimens, and concentration of β2 microglobulin at screening. Bortezomib (1·3 mg/m2) was administered intravenously until protocol amendment 1 then either intravenously or subcutaneously on days 1, 4, 8, and 11 for the first eight cycles and subsequently on days 1 and 8. Dexamethasone (20 mg [10 mg if age >75 years]) was administered orally on the same days as bortezomib and the day after. Patients allocated pomalidomide received 4 mg orally on days 1-14. Treatment cycles were every 21 days. The primary endpoint was progression-free survival in the intention-to-treat population, as assessed by an independent review committee. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled.Between Jan 7, 2013, and May 15, 2017, 559 patients were enrolled. 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were allocated bortezomib and dexamethasone. Median follow-up was 15·9 months (IQR 9·9-21·7). Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortezomib and dexamethasone (median 11·20 months [95% CI 9·66-13·73] vs 7·10 months [5·88-8·48]; hazard ratio 0·61, 95% CI 0·49-0·77; p<0·0001). 278 patients received at least one dose of pomalidomide, bortezomib, and dexamethasone and 270 patients received at least one dose of bortezomib and dexamethasone, and these patients were included in safety assessments. The most common grade 3 or 4 treatment-emergent adverse events were neutropenia (116 [42%] of 278 patients vs 23 [9%] of 270 patients; nine [3%] vs no patients had febrile neutropenia), infections (86 [31%] vs 48 [18%]), and thrombocytopenia (76 [27%] vs 79 [29%]). Serious adverse events were reported in 159 (57%) of 278 patients versus 114 (42%) of 270 patients. Eight deaths were related to treatment; six (2%) were recorded in patients who received pomalidomide, bortezomib, and dexamethasone (pneumonia [n=2], unknown cause [n=2], cardiac arrest [n=1], cardiorespiratory arrest [n=1]) and two (1%) were reported in patients who received bortezomib and dexamethasone (pneumonia [n=1], hepatic encephalopathy [n=1]).Patients with relapsed or refractory multiple myeloma who previously received lenalidomide had significantly improved progression-free survival when treated with pomalidomide, bortezomib, and dexamethasone compared with bortezomib and dexamethasone. Adverse events accorded with the individual profiles of pomalidomide, bortezomib, and dexamethasone. This study supports use of pomalidomide, bortezomib, and dexamethasone as a treatment option in patients with relapsed or refractory multiple myeloma who previously received lenalidomide.Celgene." @default.
• W2945852816 created "2019-05-29" @default.
• W2945852816 creator A5088425600 @default.
• W2945852816 date "2019-06-01" @default.
• W2945852816 modified "2023-10-11" @default.
• W2945852816 title "Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial" @default.
• W2945852816 cites W1978643311 @default.
• W2945852816 cites W1985864219 @default.
• W2945852816 cites W1988265934 @default.
• W2945852816 cites W1988998251 @default.
• W2945852816 cites W1999549312 @default.
• W2945852816 cites W2044436186 @default.
• W2945852816 cites W2066700805 @default.
• W2945852816 cites W2066713758 @default.
• W2945852816 cites W2091773528 @default.
• W2945852816 cites W2096367061 @default.
• W2945852816 cites W2123159083 @default.
• W2945852816 cites W2125477622 @default.
• W2945852816 cites W2136541422 @default.
• W2945852816 cites W2193716145 @default.
• W2945852816 cites W2201190784 @default.
• W2945852816 cites W2287899290 @default.
• W2945852816 cites W2343386476 @default.
• W2945852816 cites W2394652810 @default.
• W2945852816 cites W2443618845 @default.
• W2945852816 cites W2465965969 @default.
• W2945852816 cites W2512106959 @default.
• W2945852816 cites W2512928744 @default.
• W2945852816 cites W2528329272 @default.
• W2945852816 cites W2528979204 @default.
• W2945852816 cites W2588087999 @default.
• W2945852816 cites W2606454205 @default.
• W2945852816 cites W2620016413 @default.
• W2945852816 cites W2620717562 @default.
• W2945852816 cites W2772248651 @default.
• W2945852816 cites W2776818949 @default.
• W2945852816 cites W2890273388 @default.
• W2945852816 cites W2892230801 @default.
• W2945852816 cites W2894981552 @default.
• W2945852816 cites W2900068404 @default.
• W2945852816 cites W2904818757 @default.
• W2945852816 cites W2908410142 @default.
• W2945852816 cites W2913073599 @default.
• W2945852816 doi "https://doi.org/10.1016/s1470-2045(19)30152-4" @default.
• W2945852816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31097405" @default.
• W2945852816 hasPublicationYear "2019" @default.
• W2945852816 type Work @default.
• W2945852816 sameAs 2945852816 @default.
• W2945852816 citedByCount "231" @default.
• W2945852816 countsByYear W29458528162019 @default.
• W2945852816 countsByYear W29458528162020 @default.
• W2945852816 countsByYear W29458528162021 @default.
• W2945852816 countsByYear W29458528162022 @default.
• W2945852816 countsByYear W29458528162023 @default.
• W2945852816 crossrefType "journal-article" @default.
• W2945852816 hasAuthorship W2945852816A5088425600 @default.
• W2945852816 hasConcept C121332964 @default.
• W2945852816 hasConcept C126322002 @default.
• W2945852816 hasConcept C141071460 @default.
• W2945852816 hasConcept C142424586 @default.
• W2945852816 hasConcept C143998085 @default.
• W2945852816 hasConcept C203092338 @default.
• W2945852816 hasConcept C2776063141 @default.
• W2945852816 hasConcept C2776364478 @default.
• W2945852816 hasConcept C2777478702 @default.
• W2945852816 hasConcept C2778524551 @default.
• W2945852816 hasConcept C2779609412 @default.
• W2945852816 hasConcept C2780401358 @default.
• W2945852816 hasConcept C2781413609 @default.
• W2945852816 hasConcept C2908647359 @default.
• W2945852816 hasConcept C535046627 @default.
• W2945852816 hasConcept C71924100 @default.
• W2945852816 hasConcept C87355193 @default.
• W2945852816 hasConcept C99454951 @default.
• W2945852816 hasConceptScore W2945852816C121332964 @default.
• W2945852816 hasConceptScore W2945852816C126322002 @default.
• W2945852816 hasConceptScore W2945852816C141071460 @default.
• W2945852816 hasConceptScore W2945852816C142424586 @default.
• W2945852816 hasConceptScore W2945852816C143998085 @default.
• W2945852816 hasConceptScore W2945852816C203092338 @default.
• W2945852816 hasConceptScore W2945852816C2776063141 @default.
• W2945852816 hasConceptScore W2945852816C2776364478 @default.
• W2945852816 hasConceptScore W2945852816C2777478702 @default.
• W2945852816 hasConceptScore W2945852816C2778524551 @default.
• W2945852816 hasConceptScore W2945852816C2779609412 @default.
• W2945852816 hasConceptScore W2945852816C2780401358 @default.
• W2945852816 hasConceptScore W2945852816C2781413609 @default.
• W2945852816 hasConceptScore W2945852816C2908647359 @default.
• W2945852816 hasConceptScore W2945852816C535046627 @default.
• W2945852816 hasConceptScore W2945852816C71924100 @default.
• W2945852816 hasConceptScore W2945852816C87355193 @default.
• W2945852816 hasConceptScore W2945852816C99454951 @default.
• W2945852816 hasIssue "6" @default.
• W2945852816 hasLocation W29458528161 @default.
• W2945852816 hasLocation W29458528162 @default.
• W2945852816 hasOpenAccess W2945852816 @default.
• W2945852816 hasPrimaryLocation W29458528161 @default.
• W2945852816 hasRelatedWork W1996365535 @default.

• next